Is the Options Market Predicting a Spike in Wyndham Hotels Stock? — Neutral

WH   Zacks Investment Research — December 17, 2025

Investors need to pay close attention to WH stock based on the movements in the options market lately.

image for news Is the Options Market Predicting a Spike in Wyndham Hotels Stock?

The Zacks Analyst Blog Capital One Financial, SoFi and OppFi — Positive

COF  OPFI  SOFI   Zacks Investment Research — December 17, 2025

Capital One Financial stands to gain as digital payments grow, rates ease and consumer spending stays strong, extending momentum in payment stocks into 2026.

image for news The Zacks Analyst Blog Capital One Financial, SoFi and OppFi

Chegg vs. Udemy: Which EdTech Stock Has the Edge Heading Into 2026? — Neutral

CHGG  UDMY   Zacks Investment Research — December 17, 2025

The online education market is undergoing a structural reset as learner behavior shifts toward flexible, outcome-oriented skill development and generative AI reshapes how knowledge is consumed. Within this evolving edtech landscape, Chegg, Inc. CHGG and Udemy, Inc. UDMY represent two distinct approaches to monetizing digital learning platforms, each responding to similar industry pressures from very different starting points.

image for news Chegg vs. Udemy: Which EdTech Stock Has the Edge Heading Into 2026?

LOS ANGELES, Dec. 17, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fermi Inc. (“Fermi” or “the Company”) (NASDAQ: FRMI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

image for news FRMI Investors Have Opportunity to Join Fermi Inc. Fraud Investigation with the Schall Law Firm

DENVER--(BUSINESS WIRE)--HRSoft, Inc., a provider of enterprise compensation management software, today announced it has joined the Workday Partner Program and has launched the HRSoft: Compensation Platform Marketplace App, a Workday Designed Approved integration. The partnership expands the Workday ecosystem with solutions that help financial-services organizations manage complex compensation programs with precision, transparency, and scale. HRSoft's compensation lifecycle platform integrates.

image for news HRSoft Joins the Workday Partner Program, Expanding Compensation Capabilities for Financial-Services Organizations

Nvidia: Traders 'Remain Bullish,' And So Do I — Positive

NVDA   Seeking Alpha — December 17, 2025

Nvidia Corporation offers a compelling long-term entry after a 14% pullback, with bullish sentiment and robust AI-driven growth. NVDA's data center revenue surged 66% YoY in FQ3 2026, with $500B in confirmed AI chip orders and strong partnerships fueling demand. Valuation has become attractive: NVDA's P/E dropped to 44, below its five-year average, implying 11–50% upside depending on scenario.

image for news Nvidia: Traders 'Remain Bullish,' And So Do I

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Stride To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Stride between October 22, 2024 and October 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Dec. 17, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Stride, Inc. ("Stride" or the "Company") …

image for news SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Stride

FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug — Positive

ADAG   Zacks Investment Research — December 17, 2025

Adagene jumps 13.8% after the FDA grants Fast Track Status to muzastotug with pembrolizumab for MSS metastatic colorectal cancer.

image for news FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug

Canadian Natural's 2026 Budget Aims to Expand Assets and Production — Positive

CNQ   Zacks Investment Research — December 17, 2025

CNQ targets 3% production growth in 2026 with a C$6.3B budget, disciplined capital and a balanced liquids-gas mix to drive shareholder value.

image for news Canadian Natural's 2026 Budget Aims to Expand Assets and Production

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Bitdeer To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Bitdeer between June 6, 2024 and November 10, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Dec. 17, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bitdeer Technologies Group ("Bitdeer" or the …

image for news SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bitdeer Technologies

3 Top-Ranked AI-Driven Computer Storage Devices Stocks to Buy for 2026 — Positive

STX  TDC  WDC   Zacks Investment Research — December 17, 2025

WDC, TDC and STX ride on cloud and AI storage demand as data center momentum sets the stage for 2026.

image for news 3 Top-Ranked AI-Driven Computer Storage Devices Stocks to Buy for 2026

Jabil (JBL) Surpasses Q1 Earnings and Revenue Estimates — Positive

JBL   Zacks Investment Research — December 17, 2025

Jabil (JBL) came out with quarterly earnings of $2.85 per share, beating the Zacks Consensus Estimate of $2.72 per share. This compares to earnings of $2 per share a year ago.

image for news Jabil (JBL) Surpasses Q1 Earnings and Revenue Estimates

Broadcom: Q4 Confirms The Company's Position At The Core Of AI Infrastructure — Positive

AVGO   Seeking Alpha — December 17, 2025

Broadcom Inc. reported robust double-digit top-line growth driven by hyperscaler demand for custom accelerators and switches, with semiconductor segment AI revenue up 74%. Robust momentum in the AI semiconductor business and elevated Backlog expected to support sustained double-digit growth through FY26. With fundamentals intact, strong demand visibility, and valuation reset after the recent pullback, AVGO offers an attractive long-term opportunity, supporting a Buy rating.

image for news Broadcom: Q4 Confirms The Company's Position At The Core Of AI Infrastructure

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Alexandria To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Alexandria between January 27, 2025 and October 27, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Dec. 17, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Alexandria Real Estate Equities, Inc. ("Alexandria" …

image for news SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alexandria Real Estate Equities

Amazon may tie $10B OpenAI investment to its AI chips — Positive

AMZN   Proactive Investors — December 17, 2025

Amazon.com Inc (NASDAQ:AMZN) is in talks to invest as much as $10 billion in OpenAI and provide the artificial intelligence startup with access to its own AI chips, according to reports. The proposed investment, first reported by The Information, would deepen ties between two of the most influential players in artificial intelligence and underscore the increasingly interconnected nature of major AI partnerships, a structure that has drawn heightened investor scrutiny.

image for news Amazon may tie $10B OpenAI investment to its AI chips

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Synopsys To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Synopsys between December 4, 2024 and September 9, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Dec. 17, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Synopsys, Inc. ("Synopsys" or the "Company") …

image for news SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Synopsys

5 Stocks Worth Watching on Their Recent Dividend Hikes — Negative

CNP  NVT  PCG  PNR  VAC   Zacks Investment Research — December 17, 2025

PNR, NVT, CNP, VAC and PCG stand out as dividend payers as market volatility persists, with each company recently announcing higher shareholder payouts.

image for news 5 Stocks Worth Watching on Their Recent Dividend Hikes

SUNNYVALE, Calif.--(BUSINESS WIRE)--Knightscope, Inc. (NASDAQ: KSCP), a leader in autonomous security robots and emergency communication devices, today announced that on the heels of the 2025 Letter from the CEO on establishing the nation's first Autonomous Security Force, the Company has exceeded yet another $1 million milestone in new sales, client renewals and expansions. Knightscope believes its recent sales activity reflects continued momentum and growing interest in the Company's technolo.

image for news Knightscope Accelerates Past Another $1 Million in New Sales, Renewals & Expansions

WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify global compound-specific, drug-regulated effects in the intact cell which is deployed for rational drug design and predictive clinical development, today announced it will be providing ACR-368 and ACR-2316 clinical data and other updates via a conference call and webcast in January 2026.

image for news UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In CarMax To Contact Him Directly To Discuss Their Options If you suffered losses in CarMax between June 20, 2025 and September 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Dec. 17, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against CarMax, Inc. ("CarMax" or the "Company") (NYSE: KMX) …

image for news SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CarMax